William B. Raich Ph.D.
Bill Raich focuses his practice on patent litigation and pre-litigation client counseling involving pharmaceuticals, biologics, medical devices, and diagnostics.
Dr. Raich has substantial experience with traditional patent litigation, Abbreviated New Drug Application (ANDA) litigation, arbitration, and contentious proceedings before the U.S. Patent and Trademark Office (USPTO). He has briefed and argued motions, taken witness testimony, conducted depositions, managed discovery and pretrial phases of complex litigations, and also drafted briefs in appeals before the Federal Circuit and U.S. Supreme Court. In addition to his litigation work, Dr. Raich performs client counseling and opinion work, primarily in areas related to biologics and pharmaceuticals, advising clients regarding their patent portfolios and patent licenses.
Prior to joining the firm, Dr. Raich conducted post-doctoral research in molecular biology and neuroscience in the laboratory of Nobel Laureate Eric Kandel at Columbia University.
Dr. Raich is an adjunct professor at George Mason University School of Law, where he teaches a course on patent litigation and dispute resolution. He also speaks regularly at conferences on issues relating to biologics.
- Represented innovative companies, including AbbVie, AstraZeneca, and Eli Lilly, in district courts and before the Federal Circuit.
- Served as a law clerk to the Honorable Jimmie V. Reyna, U.S. Court of Appeals for the Federal Circuit, 2011.
- Served as a law clerk to the Honorable Randall R. Rader, U.S. Court of Appeals for the Federal Circuit, 2010-2011.
- Drafted numerous license agreements for top multinational patent management company.
- Represented pro bono, including as lead counsel, multiple disabled veterans before the U.S. Court of Appeals for Veteran's Affairs.
- Recognized as a Washington, D.C. "Rising Star" in Intellectual Property, Super Lawyers published by Thomson Reuters, 2014-2016.
- Coauthor. "Federal Circuit Decision in Ariosa v. Sequenom Offers Further Clarification on the Scope of Patent-Eligible Subject Matter," Intellectual Property & Technology Law Journal, Sept. 2015.
- Coauthor. "Biosimilar Litigation: Lessons so Far," Pharmaceutical Executive, Aug. 2015.
- Coauthor. "Litigating Induced Infringement After Commil," Intellectual Property Today, Dec. 9, 2014.
- Coauthor. "Preparing Pharma for Generics' IPR Attacks," BNA Pharmaceutical Law and Industry Report, Aug. 15, 2014.
- Coauthor. "Patent Reform Series: A Practical Guide to Supplemental Examination," Managing Intellectual Property, June 14, 2012.
- Coauthor. "Tempest in a Teapot? An Evaluation of the Heightened Standard for Initiating Inter Partes Reexamination and Implications for Inter Partes Review," BNA's Patent, Trademark & Copyright Journal, March 30, 2012.
- Coauthor. "Strategic Planning in the Wake of the New Prior Art Provisions in the America Invents Act," CIPA Journal, Dec. 2011.
- "Term of Degree 'Readily' Not Indefinite," ipFrontline, 2010.
- Coauthor. "Surviving an Obviousness Patent Challenge," Drug Discovery & Development, Oct. 27, 2008.
- Coauthor. "Litigating Patent Obviousness," Bio IT World, Oct. 2008.